Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: A case report

被引：4
作者：
Bhattacharya S. [1 ]
Choudhury A. [2 ]
Ravi S. [2 ]
Morrissey J. [3 ]
Mathew G. [1 ]
机构：
[1] Department of General Surgery, George Eliot Hospital, Nuneaton, Warwickshire CV10 7DJ, College Street
[2] Department of General Surgery, Victoria Hospital, Blackpool, Lancashire FY3 8NR, Whinney Heys Road
[3] Institute of Clinical Sciences, Warwick Medical School
来源：
Journal of Medical Case Reports | / 2卷 / 1期
关键词：
Imatinib; Computerise Tomography; Mitotic Count; Minor Side Effect; Paracolic Gutter;
D O I：
10.1186/1752-1947-2-110
中图分类号：
学科分类号：
摘要：
Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO performance status zero. Case Presentation: A 68 year old female was diagnosed with unresectable GIST in the duodenum with metastasis to liver, pancreas and omentum in November 2001. She was commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the medical records and radiology reports. She had good tolerance with stable disease. After six years her CT scan showed no disease progression and her WHO performance status was zero. Conclusion: This report supports the view that imatinib is a safe and effective drug in controlling disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life. © 2008 Bhattacharya et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 11 条
  • [1] Sakakura C., Hagiwara A., Soga K., Miyagawa K., Nakashima S., Yoshikawa T., Kin S., Nakase Y., Yamaoka N., Sagara Y., Yamagishi H., Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy, World Journal of Gastroenterology, 12, 17, pp. 2793-2797, (2006)
  • [2] Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours, Technology Appraisal Guidance 86, Guidelines on GIST
  • [3] Miettinen M., Lasota J., Gastrointestinal stromal tumors: Pathology and prognosis at different sites, Seminars in Diagnostic Pathology, 23, 2, pp. 70-83, (2006)
  • [4] Bearzi I., Mandolesi A., Arduini F., Costagliola A., Ranaldi R., Gastrointestinal stromal tumor. A study of 158 cases: Clinicopathological features and prognostic factors, Analytical and Quantitative Cytology and Histology/The International Academy of Cytology (and) American Society of Cytology, 28, 3, pp. 137-147, (2006)
  • [5] Emile J.F., Tabone-Eqlinqer S., Theou-Anton N., Lemoine A., Prognostic value of KIT exon 11 deletions in GISTs, Gastroenterology, 131, 3, pp. 976-978, (2006)
  • [6] Martin J., Poveda A., Llombart-Bosch A., Ramos R., Lopez-Guerrero J.A., Garcia del Muro J., Maurel J., Calabuig S., Guttierrez A., Gonzalez de Sande J.L., Martinez J., De Juan A., Lainez N., Losa F., Alija V., Escudero P., Casado A., Garcia P., Blanco R., Buesa J.M., Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: A study by the Spanish Group for Sarcoma Research (GEIS), Journal of Clinical Onco
  • [7] Singer S., Rubin B.P., Lux M.L., Chen C.J., Demetri G.D., Fletcher C.D., Fletcher J.A., Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal stromal tumors, Journal of Clinical Oncology, 20, 18, pp. 3898-3905, (2002)
  • [8] Andersson J., Bumming P., Meis-Kindblom J.M., Sihto H., Nupponen N., Joensuu H., Oden A., Gustavsson B., Kindblom L.G., Nilsson B., Gastrointestinal stromal tumors with KIT exon11 deletions are associated with poor prognosis, Gastroenterology, 130, 6, pp. 1573-1581, (2006)
  • [9] Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H., Roberts P.J., Eisenberg B.L., von Mehren M., Fletcher C.D., Sandau K., McDougall K., Ou W.B., Chen C.J., Fletcher J.A., Molecular correlates of imatinib resistance in gastrointestinal stromal tumors, Journal of Clinical Oncology, 24, 29, pp. 4764-4774, (2006)
  • [10] Hornick J.L., Fletcher C.D., The role of KIT in the management of patients with gastrointestinal stromal tumours, Human Pathology, 38, 5, pp. 679-687, (2007)
12